Global and United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report & Forecast 2022-2028

Global and United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report & Forecast 2022-2028

Table of Contents
1 Study Coverage
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product Introduction
1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume for the Year 2017-2028
1.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume for the Year 2017-2028
1.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Pulmonary Arterial Hypertension (PAH) Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Pulmonary Arterial Hypertension (PAH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Pulmonary Arterial Hypertension (PAH) Drugs Market Dynamics
1.5.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
1.5.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
1.5.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
1.5.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Segment by Type
2.1.1 Inhalation
2.1.2 Injectables
2.1.3 Oral Administration
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
2.3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
3.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
3.3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Pulmonary Arterial Hypertension (PAH) Drugs Competitor Landscape by Company
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Company
4.1.1 Top Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2017-2022)
4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Concentration Ratio (CR)
4.2.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs in 2021
4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Company
4.5.1 Top Pulmonary Arterial Hypertension (PAH) Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Players (2020, 2021 & 2022)
5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region
5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Corporation Information
7.1.2 Pfizer Description and Business Overview
7.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.1.5 Pfizer Recent Development
7.2 Glaxosmithkline
7.2.1 Glaxosmithkline Corporation Information
7.2.2 Glaxosmithkline Description and Business Overview
7.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.2.5 Glaxosmithkline Recent Development
7.3 Novartis
7.3.1 Novartis Corporation Information
7.3.2 Novartis Description and Business Overview
7.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.3.5 Novartis Recent Development
7.4 United Therapeutics
7.4.1 United Therapeutics Corporation Information
7.4.2 United Therapeutics Description and Business Overview
7.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.4.5 United Therapeutics Recent Development
7.5 AstraZeneca
7.5.1 AstraZeneca Corporation Information
7.5.2 AstraZeneca Description and Business Overview
7.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.5.5 AstraZeneca Recent Development
7.6 Merck
7.6.1 Merck Corporation Information
7.6.2 Merck Description and Business Overview
7.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.6.5 Merck Recent Development
7.7 Bayer Healthcare
7.7.1 Bayer Healthcare Corporation Information
7.7.2 Bayer Healthcare Description and Business Overview
7.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.7.5 Bayer Healthcare Recent Development
7.8 Actelion Pharmaceuticals
7.8.1 Actelion Pharmaceuticals Corporation Information
7.8.2 Actelion Pharmaceuticals Description and Business Overview
7.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.8.5 Actelion Pharmaceuticals Recent Development
7.9 Daiichi Sankyo
7.9.1 Daiichi Sankyo Corporation Information
7.9.2 Daiichi Sankyo Description and Business Overview
7.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.9.5 Daiichi Sankyo Recent Development
7.10 Northern Therapeutics
7.10.1 Northern Therapeutics Corporation Information
7.10.2 Northern Therapeutics Description and Business Overview
7.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.10.5 Northern Therapeutics Recent Development
7.11 Aires Pharmaceuticals
7.11.1 Aires Pharmaceuticals Corporation Information
7.11.2 Aires Pharmaceuticals Description and Business Overview
7.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
7.11.5 Aires Pharmaceuticals Recent Development
7.12 Arena Pharmaceuticals
7.12.1 Arena Pharmaceuticals Corporation Information
7.12.2 Arena Pharmaceuticals Description and Business Overview
7.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Arena Pharmaceuticals Products Offered
7.12.5 Arena Pharmaceuticals Recent Development
7.13 Berlin Cures
7.13.1 Berlin Cures Corporation Information
7.13.2 Berlin Cures Description and Business Overview
7.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Berlin Cures Products Offered
7.13.5 Berlin Cures Recent Development
7.14 Eiger BioPharmaceuticals
7.14.1 Eiger BioPharmaceuticals Corporation Information
7.14.2 Eiger BioPharmaceuticals Description and Business Overview
7.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Eiger BioPharmaceuticals Products Offered
7.14.5 Eiger BioPharmaceuticals Recent Development
7.15 Reata Pharmaceuticals
7.15.1 Reata Pharmaceuticals Corporation Information
7.15.2 Reata Pharmaceuticals Description and Business Overview
7.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Reata Pharmaceuticals Products Offered
7.15.5 Reata Pharmaceuticals Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Chain Analysis
8.2 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors
8.3 Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process
8.4 Pulmonary Arterial Hypertension (PAH) Drugs Sales and Marketing
8.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels
8.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors
8.5 Pulmonary Arterial Hypertension (PAH) Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Pulmonary Arterial Hypertension (PAH) Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
Table 3. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
Table 4. Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges
Table 5. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturer, (K Pcs), 2017-2022
Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2017-2022) & (USD/Pcs)
Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2021)
Table 18. Top Players of Pulmonary Arterial Hypertension (PAH) Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 20. Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Pulmonary Arterial Hypertension (PAH) Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Players, (K Pcs), 2020, 2021 & 2022
Table 26. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2017-2022) & (K Pcs)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 33. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2017-2028) & (K Pcs)
Table 35. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 37. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 39. Latin Americaa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 41. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Pfizer Corporation Information
Table 43. Pfizer Description and Business Overview
Table 44. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 45. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 46. Pfizer Recent Development
Table 47. Glaxosmithkline Corporation Information
Table 48. Glaxosmithkline Description and Business Overview
Table 49. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 50. Glaxosmithkline Product
Table 51. Glaxosmithkline Recent Development
Table 52. Novartis Corporation Information
Table 53. Novartis Description and Business Overview
Table 54. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 55. Novartis Product
Table 56. Novartis Recent Development
Table 57. United Therapeutics Corporation Information
Table 58. United Therapeutics Description and Business Overview
Table 59. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 60. United Therapeutics Product
Table 61. United Therapeutics Recent Development
Table 62. AstraZeneca Corporation Information
Table 63. AstraZeneca Description and Business Overview
Table 64. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 65. AstraZeneca Product
Table 66. AstraZeneca Recent Development
Table 67. Merck Corporation Information
Table 68. Merck Description and Business Overview
Table 69. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 70. Merck Product
Table 71. Merck Recent Development
Table 72. Bayer Healthcare Corporation Information
Table 73. Bayer Healthcare Description and Business Overview
Table 74. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 75. Bayer Healthcare Product
Table 76. Bayer Healthcare Recent Development
Table 77. Actelion Pharmaceuticals Corporation Information
Table 78. Actelion Pharmaceuticals Description and Business Overview
Table 79. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 80. Actelion Pharmaceuticals Product
Table 81. Actelion Pharmaceuticals Recent Development
Table 82. Daiichi Sankyo Corporation Information
Table 83. Daiichi Sankyo Description and Business Overview
Table 84. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 85. Daiichi Sankyo Product
Table 86. Daiichi Sankyo Recent Development
Table 87. Northern Therapeutics Corporation Information
Table 88. Northern Therapeutics Description and Business Overview
Table 89. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 90. Northern Therapeutics Product
Table 91. Northern Therapeutics Recent Development
Table 92. Aires Pharmaceuticals Corporation Information
Table 93. Aires Pharmaceuticals Description and Business Overview
Table 94. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 95. Aires Pharmaceuticals Product
Table 96. Aires Pharmaceuticals Recent Development
Table 97. Arena Pharmaceuticals Corporation Information
Table 98. Arena Pharmaceuticals Description and Business Overview
Table 99. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 100. Arena Pharmaceuticals Product
Table 101. Arena Pharmaceuticals Recent Development
Table 102. Berlin Cures Corporation Information
Table 103. Berlin Cures Description and Business Overview
Table 104. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 105. Berlin Cures Product
Table 106. Berlin Cures Recent Development
Table 107. Eiger BioPharmaceuticals Corporation Information
Table 108. Eiger BioPharmaceuticals Description and Business Overview
Table 109. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Eiger BioPharmaceuticals Product
Table 111. Eiger BioPharmaceuticals Recent Development
Table 112. Reata Pharmaceuticals Corporation Information
Table 113. Reata Pharmaceuticals Description and Business Overview
Table 114. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. Reata Pharmaceuticals Product
Table 116. Reata Pharmaceuticals Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Pulmonary Arterial Hypertension (PAH) Drugs Customers List
Table 120. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2017-2028 (K Pcs)
Figure 5. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales 2017-2028 (K Pcs)
Figure 8. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share in Global, in Volume (K Pcs) 2017-2028
Figure 10. Pulmonary Arterial Hypertension (PAH) Drugs Report Years Considered
Figure 11. Product Picture of Inhalation
Figure 12. Product Picture of Injectables
Figure 13. Product Picture of Oral Administration
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2022 & 2028
Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type (2017-2028)
Figure 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) & (K Pcs)
Figure 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2028) & (USD/Pcs)
Figure 20. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2022 & 2028
Figure 21. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type (2017-2028)
Figure 23. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) & (K Pcs)
Figure 24. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 25. United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2028) & (USD/Pcs)
Figure 26. Product Picture of Hospitals
Figure 27. Product Picture of Clinics
Figure 28. Product Picture of Other
Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2022 & 2028
Figure 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application (2017-2028)
Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) & (K Pcs)
Figure 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2028) & (USD/Pcs)
Figure 35. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2022 & 2028
Figure 36. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 37. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application (2017-2028)
Figure 38. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) & (K Pcs)
Figure 39. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 40. United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2028) & (USD/Pcs)
Figure 41. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 42. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 43. U.S. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 44. Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 47. Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. France Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 53. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 54. China Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. India Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Thailand Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Malaysia Pulmonary Arterial Hypert

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Pulmonary Arterial Hypertension (Pah) Medicine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 103

Market Overview of Global Pulmonary Arterial Hypertension (Pah) Medicine market: According to our latest research, the global Pulmonary Arterial Hypertension (Pah) Medicine market looks promising in the next 5 years. As of 2022, the global Pulmonary Arterial Hypertension (Pah) Medicine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to ......

Global Nifedipine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Nifedipine market: According to our latest research, the global Nifedipine market looks promising in the next 5 years. As of 2022, the global Nifedipine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Nifedipine market, with a systematical de......

Global Amlodipine Besylate Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 115

The Amlodipine Besylate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amlodipine Besylate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profil......

Pulmonary Arterial Hypertension (PAH) Drugs - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 112

The global Pulmonary Arterial Hypertension (PAH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other,, are propelling Pulmonary Arterial Hypertension (PAH) Drugs market. Inhalation, one of the segments analysed in this report, is projected to record % ......

Captopril API - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 100

The global Captopril API market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Captopril API in various end use industries. The expanding demands from the Captopril Tablet, Compound Captopril Tablet and Captopril Injection,, are propelling Captopril API market. 98% Captopril API, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the......

Telmisartan - Global Market Insights and Sales Trends 2024

Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 107

The global Telmisartan market size is expected to reach US$ 3631.3 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Telmisartan in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Telmisartan market. Injection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-Dried......

Global Ambrisentan Professional Survey Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 106

Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......

Global Ambrisentan Market Research Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 2680 Onwards        Pages: 132

Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......

Global Amlodipine Besylate Professional Survey Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 133

Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs